Pharmacological modulation of mitochondrial calcium uniporter controls lung inflammation in cystic fibrosis.

Alessandro Rimessi, Chiara Pozzato, Lorenzo Carparelli, Alice Rossi, Serena Ranucci, Ida De Fino, Cristina Cigana, Anna Talarico, Mariusz R Wieckowski, Carla M P Ribeiro, Claudio Trapella, Giacomo Rossi, Giulio Cabrini, Alessandra Bragonzi, Paolo Pinton

Journal: Science advances 2022;6(19):eaax9093

PMID: 32494695

Abstract

Mitochondria physically associate with the endoplasmic reticulum to coordinate interorganelle calcium transfer and regulate fundamental cellular processes, including inflammation. Deregulated endoplasmic reticulum-mitochondria cross-talk can occur in cystic fibrosis, contributing to hyperinflammation and disease progression. We demonstrate that infection increases endoplasmic reticulum-mitochondria associations in cystic fibrosis bronchial cells by stabilizing VAPB-PTPIP51 (vesicle-associated membrane protein-associated protein B-protein tyrosine phosphatase interacting protein 51) tethers, affecting autophagy. Impaired autophagy induced mitochondrial unfolding protein response and NLRP3 inflammasome activation, contributing to hyperinflammation. The mechanism by which VAPB-PTPIP51 tethers regulate autophagy in cystic fibrosis involves calcium transfer via mitochondrial calcium uniporter. Mitochondrial calcium uniporter inhibition rectified autophagy and alleviated the inflammatory response in vitro and in vivo, resulting in a valid therapeutic strategy for cystic fibrosis pulmonary disease.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Address: Department of Medical Sciences and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy.; Center of research on Innovative Therapies for Cystic Fibrosis, University of Ferrara, 44121 Ferrara, Italy.; Department of Medical Sciences and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy.; Infections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milano, Italy.; Department of Chemistry and Pharmaceutical Sciences and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy.; Laboratory of Mitochondrial Biology and Metabolism, Nencki Institute of Experimental Biology, 02-093 Warsaw, Poland.; Department of Medicine/Pulmonary Division, Marsico Lung Institute and Cystic Fibrosis Center, Chapel Hill, NC 27599-7248, USA.; School of Biosciences and Veterinary Medicine, University of Camerino, 62024 Macerata, Italy.; Center of research on Innovative Therapies for Cystic Fibrosis, University of Ferrara, 44121 Ferrara, Italy.; Department of Neurosurgery, Biomedicine and Movement, University of Verona, 37126 Verona, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.